Hainsworth, J.D., Litchy, S., Barrom, J.H., et al. (2003) Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 1746-1751.
https://doi.org/10.1200/JCO.2003.09.027

has been cited by the following article:

• TITLE: Progress in the Treatment of Hematological Diseases with Rituximab

  AUTHORS: Xiangjun Fu, Li’e Lin, Hongxia Yao, Li Huang, Can Meng, Shuwen Wang, Dan Liu, Li Guo, Mengling Duan

  KEYWORDS: Rituximab, Malignant Lymphoma, Leukemia, Multiple Myeloma, Autoimmune Diseases, Hematopoietic Stem Cell Transplantation

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.11 No.1, March 1, 2021

  ABSTRACT: Rituximab is a mouse and human chimeric CD20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of CD20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of CD20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.